Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops therapies treating acute and chronic pain.
Year Established: | |
Funding: | |
Address: | Mountain View, CA 94040 |
Telephone: | |
Mobile: | |
Fax: | |
Mail: | info@trigemina.com |
Company URL: | http://www.trigemina.com |
Celerity Partners
Head of Clinical Research: Martin Angst, M.D.
Dr. Angst holds a full time appointment as an Associate Professor of Anesthesia at Stanford University School of Medicine. Dr. Angst is the founder and director of the Human Pain Laboratory at Stanford University Medical School. Dr. Angst pursues three inter-related areas of interest: the identification of objective pain biomarkers, the early validation or rejection of novel analgesic interventions, and the improved characterization of opioid pharmacology including genetic and immune-modulating aspects. Preclinical and clinical trials completed by Dr. Angst have been sponsored by the National Institute of Health, the Defense Advanced Research Projects Agency, and the pharmaceutical industry. Dr. Angst has published over 50 peer-reviewed articles and has authored several book chapters. Dr. Angst serves as an expert consultant in clinical pharmacology to the biotechnical, pharmaceutical and legal industry.
Dr. Angst received his MD degree from the University of Berne, Switzerland in 1993, and completed his fellowship training in Clinical Pharmacology in 1996 at the Department of Anesthesia of Stanford University Medical School.
Grant Manager: Nancy A. Federspiel, Ph.D.
Dr. Federspiel has worked both in academia as a faculty member at the University of Idaho and in biotech industry, conducting research in diverse areas including molecular immunology, light-regulated gene expression in cyanobacteria, and virulence in pathogenic bacteria. Dr. Federspiel was Associate Director at the Stanford Genome Technology Center, where she led DNA sequencing projects on organismsand the Human Genome, resulting in >60 million bases of DNA sequence deposited in GenBank. She became Director of Plant Genomics at Exelixis, Inc. where she managed plant genomics at South San Francisco and Portland, leading to several patents. In her current position as Program Officer in the Institute for Immunity, Transplantation, and Infection at Stanford University, Dr. Federspiel works to develop interdisciplinary strategic funding opportunities to advance the basic, translational, and clinical research goals of the faculty investigators and the Institute.
Nancy A. Federspiel graduated from the University of Dayton summa cum laude with a B.S. in Chemistry, and received her Ph.D. in Biochemistry from the University of Minnesota. Her postdoctoral training was at Stanford University.
William Frey II, Ph.D.
Dr. William H. Frey II is Director of the Alzheimer's Research Center at Regions Hospital in St. Paul, MN, Professor of Pharmaceutics and Oral Biology, faculty member in Neurology and Neuroscience at the University of Minnesota, and consultant to the pharmaceutical and biotechnology industry. His patents, owned by Novartis, Stanford University, the HealthPartners Research Foundation, and others, target noninvasive delivery of therapeutic agents, including stem cells, to the brain and spinal cord for treating neurological disorders, psychiatric disorders and obesity. Dr. Frey's non-invasive intranasal method for bypassing the blood-brain barrier to target CNS therapeutic agents to the brain while reducing systemic exposure and unwanted side effects has captured the interest of pharmaceutical companies and neuroscientists. Dr. Frey has over 90 publications in scientific and medical journals, such as the Journal of Biological Chemistry, Proceedings of the National Academy of Sciences, and Brain Research.
Dr. Frey earned his BA in Chemistry at Washington University in 1969 and Ph.D. in Biochemistry at Case Western Reserve University in 1975.
CEO and Chairman: Daniel Jacobs, M.D.
See under Board of Directors
Director of Preclinical Research: Jordan Mechanic, Ph.D.
Dr. Mechanic is a Research Scientist with over 10 years experience working in the field of Behavioral Pharmacology. His major research focused on establishing rodent models of substance abuse, with a particular emphasis on psychostimulants such as amphetamine and cocaine. Dr. Mechanic worked as a post-doctoral fellow and then as a Research Scientist with Roche Biosciences in the Neurobehavior Unit, developing a series of preclinical cognitive assays in order to support lead candidate selection and optimization for Alzheimer’s disease and other dementias. Dr. Mechanic has established in vivo models, and has extensive experience providing development candidate support for a wide variety of neuropsychiatric indications including; depression, anxiety, schizophrenia, dementia and substance abuse.
As a National Institute on Drug Abuse (NIDA) fellow, he received his Ph.D. in Biological Psychology with a Neuroscience specialization from the University of Oklahoma Health Sciences Center.
Head of Science: David C. Yeomans, Ph.D.
Dr. Yeomans is the Director Pain Research and a tenured Associate Professor of Anesthesia at Stanford University School of Medicine. He is the chair of the scientific advisory board of three companies and an advisor to numerous pharmaceutical and biotech companies, as well as venture capital firms and intellectual property law practices. Dr. Yeomans has authored over 60 peer reviewed articles and 11 book chapters in the field of pain, and has been the recipient of numerous NIH grants. He has authored 9 patent applications and co-founded 2 companies devoted to the management of pain.
Dr. Yeomans earned an AB degree from Dartmouth College, received his PhD in Neuroscience from the University of Florida, and completed his research training as a NIH fellow at the University of Illinois.